Dr Monica Li Lists Microneedling Considerations, Precautions

EP: 1.Ruxolitinib Cream Improves AD Across Body Regions, Shows Efficacy, Safety in Black Patients

EP: 2.Upcoming Generics Provide New Considerations and Opportunities for Savings

EP: 3.Managed Care Has a Key Role in Biosimilar Adoption, Says Cardinal's Oskouei

EP: 4.Dr John Harris: There Are a Lot of Reasons to Talk About Vitiligo at This Year’s AAD Meeting

EP: 5.Dermatologists’ Focus to Delve Below the Skin at Annual Conference

EP: 6.Experts Herald “Year of the JAK Inhibitor” in Dermatology

EP: 7.Dr Monica Li Highlights Advances in Microneedling

EP: 8.Dr Eva Parker: Climate Change Has Been Impacting Skin Diseases for Years

EP: 9.Dermatology Data Can Direct Policy Priorities, but Gaps Reflect Inequities of Care

EP: 10.Dr John Harris Outlines the Outcomes of Stopping Treatment With Ruxolitinib Cream for Vitiligo

EP: 11.Late-Breaking Abstracts Demonstrate Value of Persistence With Ruxolitinib Cream for Vitiligo

EP: 12.Examining Dermatological Care for Transgender Patients

EP: 13.How Our Understanding of Inflammatory Skin Disease Has Evolved From the 4 Humors to Targeted Therapies

EP: 14.Dr Haley Naik Discusses Using Biologics and the Drug Pipeline for Hidradenitis Suppurativa

EP: 15.Drs Dellavalle and Rodriguez Discuss Disparities in Prescription Patterns for Atopic Dermatitis

EP: 16.Posters Show Success of Ruxolitinib Cream in Alleviating Facial Vitiligo Symptoms, Reducing Noticeability

EP: 17.Investigators Highlight Disparities Evident in Skin Disease Care, Data Collection

EP: 18.Studies Presented at AAD Examine Safety and Satisfaction of Tildrakizumab for Psoriasis

EP: 19.Patients With AD Have More Options With Biologics, JAK Inhibitors, Says Dr Emma Guttman-Yassky

EP: 20.Dermatologists Looking to the Future Will Need to Be Their Own Advocates, Panel Says

EP: 21.Teledermatology Can Increase Access for Patients With High-Risk Melanoma: Erik Jaklitsch

EP: 22.Dr Sancy Leachman: Melanoma Metastasizes Quickly, Needs to Be Caught Early

EP: 23.Panel Discusses Treating Acne, Psoriasis in Dermatology Patients

EP: 24.New and Upcoming Treatment for Vitiligo, Atopic Dermatitis

EP: 25.Long-Term Safety of Dupilumab in Adults With Moderate to Severe Atopic Dermatitis

EP: 26.Evaluating Label Warnings, Switching Rates in Patients With Psoriasis Initiating New Treatment

EP: 27.ICYMI: Highlights From RAD 2023

EP: 28.AAD 2024 to Feature Topics Including JAK Inhibitors, Biologics

EP: 29.Dr Amy Paller Previews the 2024 AAD Annual Conference

EP: 30.Ruxolitinib Reduces Extent, Severity of AD and Need for Other Treatments

EP: 31.Dr Raj Chovatiya Outlines Who Is a Good Candidate for Oral JAK Inhibitors

EP: 32.Atopic Dermatitis in Adults: Challenges and Treatment Strategies

EP: 33.Dr Robert Sidbury: Understanding What Makes a Dermatology Practice Successful

EP: 34.Dr Monica Li Discusses Tailoring Microneedling Treatments to Meet Each Patient's Need

EP: 35.Skin Tone Bias Persists in Google Searches for Vitiligo

EP: 36.Management of HS Requires Both Coordination, Communication Between Patients and Providers

EP: 37.Dr Jonathan Silverberg Discusses Findings on the Safety, Efficacy of Nemolizumab at 48 Weeks

EP: 38.Biologic, Topical Therapies Both Effective in Treating AD in Skin of Color

EP: 39.Late-Breaking Abstracts Highlight Promising Therapies in AD, Hidradenitis Suppurativa

EP: 40.Dr Jeff Stark: Pain Reduction With Bimekizumab-bkzx in Patients With HS

EP: 41.Dr Martin Dahl Discusses the Pathophysiology of AD and Benefits of ANB032

EP: 42.New Study Links Social Factors to Hidradenitis Suppurativa Severity

EP: 43.Dr Laura Ferris Discusses Safety, Efficacy of JNJ-2113 in Patients With Plaque Psoriasis

EP: 44.Dr Shawn Kwatra Shares Efficacy, Safety Data of Nemolizumab in Patients With PN

EP: 45.Brodalumab Is Effective, Safe in Patients With Moderate to Severe Psoriasis

EP: 46.Patients With Vitiligo Suffer Heightened Stigma, Mental Health Risks

EP: 47.Racial Variations in Cardiovascular Outcomes Found in Hidradenitis Suppurativa Study

EP: 48.Autoimmune Comorbidities Prevalent in Patients With Vitiligo

EP: 49.Skin Cancer Incidence Highest Among Rural, SOC Individuals

EP: 50.Dupilumab Considered Safe, Effective Treatment for Adolescent, Adult Patients With AD

EP: 51.Gaps in Skincare Knowledge, Sun Protection Practice Exist Among Patients With Lupus

EP: 52.Dr Raj Chovatiya Provides Evidence Supporting Oral JAK Inhibitor Use to Treat AD

EP: 53.Undertreatment, Biologic Access Gaps Identified in Psoriasis Treatment

EP: 54.Dr Raj Chovatiya Explains Oral JAK Inhibitor Monitoring Protocols for AD Treatment

Now Viewing

EP: 55.Dr Monica Li Lists Microneedling Considerations, Precautions

EP: 56.Dr Jonathan Silverberg Describes AD Diagnosis, Treatment in Children vs Adults

EP: 57.Dr Lawrence Eichenfield Discusses Positive Results of Roflumilast Cream 0.05% in Pediatric Patients With AD

EP: 58.Dr Robert Sidbury on Implementing Value-Based Care Initiatives in a Pediatric Dermatology Practice

EP: 59.Dr Monica Li Explains Efficacy, Safety Differences Between Different Microneedling Techniques

EP: 60.Dr Lawrence Eichenfield Hopeful for New Pediatric AD Treatment Option

EP: 61.Dr Martina Porter Shares Findings on Ruxolitinib Cream in Patients With HS

This content was produced independently by The American Journal of Managed Care^® and is not endorsed by the American Academy of Dermatology.

Monica Li, medical and cosmetic dermatologist, explained the essential microneedling considerations and precautions that providers should take into account to safely implement the procedure in patients.

Li is also a clinical assistant professor at the University of British Columbia.

Transcript

What are the essential considerations and precautions for safely implementing microneedling procedures in patients, particularly in real-world clinical settings where patient profiles and skin conditions may vary widely?

We really need to think about performing any treatment for that matter, including mechanical microneedling, with the mindset of pre-treatment, during the treatment, and post-treatment considerations.

If we organize it that way, then we think about pre-treatment. So, for mechanical microneedling, it's important to, first of all, identify treatable conditions. As we know, not every single tool in medicine is meant for every single condition out there. So, we have to select the appropriate candidate, first and foremost, to make that treatment safe and effective. Some of the treatable conditions that have been published in the literature, been demonstrated in studies, to work with mechanical microneedling includes scars, stretch marks, wrinkles, rhytides, and enlarged pores.

Of course, other than identifying the appropriate patient, once we determine that in the consultation process, it's important to avoid treating actively infected or inflamed skin. For instance, if a patient has oral herpes that's an active lesion, or if they have a flare up of their acne or eczema, then those are circumstances where that particular affected area of the skin, there should be no mechanical microneedling perform.

Now, just like many other treatments, we need to prep the skin before we deliver the treatment with an antimicrobial cleanser, and, for patient comfort to tolerate the treatment, we often will recommend the application of a topical anesthetic; in my practice, I use a compounded topical 30% lidocaine.

Beyond that, we should also avoid treating tan skin just out of an abundance of precaution. Even though mechanical microneedling is relatively considered colorblind, it's still important that if a patient returns to our office after a consultation and they show signs of an acute tan that we're not treating right there and then and asking the patient to return in 2 to 4 weeks so that the inflammation that is created by our treatment does not worsen or increase the risk of postprocedure dispigmentation.

With that in mind, then we think about during the treatment, so some considerations. When we're actually delivering the treatment, we should apply manual skin traction so that there is smooth delivery of microneedles into the skin. When we're delivering the treatment, the device, because this is a handheld electric motor power device, should be held perpendicular to the skin to ensure that there's even penetration of those tiny needles into the dermis. There's a gliding gel that we can use, depending on which tool and which screening device you end up choosing in your office, to facilitate movement of that device tip over the skin. A cross hatching technique should be applied so that you're not having skip areas that result after the treatment.

Similar to lasers, we always think about tissue clinical endpoint when we're treating to guide our parameters. Similarly, with mechanical microneedling, a useful guide for us for a treatment endpoint is to observe for pinpoint bleeding. In some cases, if we see a blurring or effacement of the targeted site, I can give an example where, for instance, if we're treating upper eyelid wrinkles, those vertical barcode lines, then a little bit of blurring because of the immediate post procedure edema is what I am referring to when I'm talking about effacement.

Then, this brings us to post-treatment. Of course, there's also a number of considerations. After we deliver the microneedling treatment for our patients, we have to apply cool, wet compresses to make sure there's hemostasis that's achieved. Often, we apply a soothing balm, ointment, or a sheet mask for comfort, to cool the skin, and also to just facilitate the treatment.

In my office, I use a biocellulose mask, which is basically a water-concentrated mask that patients often feel is very nice and calming on their skin afterwards. We have to educate our patients to avoid applying any actives, especially immediately after the treatment, but also within the first several days, until the post procedure redness and puffiness resolves. This is important so that we don't further irritate the skin. So, active [ingredients] I'm referring to would include things like topical retinols, retinoids. salicylic acid.

Patients really should not be applying makeup for at least the first 24 hours after treatment, as well. That's because there's these little micro channels in the skin. We don't want contamination from makeup products through those little channels after our treatment, and it takes at least as histology studies have shown at least 4 hours, if not longer, to close.

Finally, because we see this being reported, although not commonly, in the literature for microneedling treatment as a side effect, patients and clinicians should avoid application of any topical agents that are not approved for intradermal use. The reason is because we want to prevent potential allergic contact dermatitis and also possible granuloma formation from use of these products that are not meant to go through into the skin.